阿司匹林加重呼吸系统疾病:发病机制和治疗策略

doi:10.19982/j.issn.1000-6621.20240216

中国防痨杂志 ›› 2024, Vol. 46 ›› Issue (11): 1400-1405.doi: 10.19982/j.issn.1000-6621.20240216

阿司匹林加重呼吸系统疾病:发病机制和治疗策略

明文华¹^,², 马婷婷¹^,²(), 王洪田¹^,², 王学艳¹^,²

¹首都医科大学附属北京世纪坛医院变态反应科,北京 100038
²首都医科大学附属北京世纪坛医院变态反应中心,北京 100038

收稿日期:2024-05-28 出版日期:2024-11-10 发布日期:2024-10-31
通信作者: 马婷婷,Email: Feixue_20048@163.com
基金资助:
北京世纪坛医院院内基金(2023-q11);北京世纪坛医院院内基金(2022-C08);中国国家铁路集团有限公司科技研究开发计划课题(J2022Z601);鄂尔多斯市科技计划“揭榜挂帅”项目(JBGS-2021-006);内蒙古自治区卫生健康委2023年首府地区公立医院高水平临床专科建设项目之科技项目(2023SGGZ027);2024年首都卫生发展科研专项自主创新项目(首发2024-2-2089)

Aspirin-exacerbated respiratory diseases: pathogenesis and treatment strategies

Ming Wenhua¹^,², Ma Tingting¹^,²(), Wang Hongtian¹^,², Wang Xueyan¹^,²

¹Allergy Department, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
²Allergy Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

Received:2024-05-28 Online:2024-11-10 Published:2024-10-31
Contact: Ma Tingting, Email: Feixue_20048@163.com
Supported by:
The Foundation of Beijing Shijitan Hospital(2023-q11);The Foundation of Beijing Shijitan Hospital(2022-C08);Science and Technology Research and Development Program of China National Railway Group Co., LTD(J2022Z601);Ordos City Science and Technology Plan “Unveiled” Project(JBGS-2021-006);The Inner Mongolia Autonomous Region Health Committee in 2023, the Capital of Public Hospitals, High Level Clinical Subject Construction Project of Science and Technology Project(2023SGGZ027);Capital’s Funds for Health Improvement and Research (CFH 2024-2-2089)

摘要/Abstract

摘要：

阿司匹林加重呼吸系统疾病(aspirin-exacerbated respiratory diseases,AERD)是一种临床疾病,包括慢性鼻窦炎伴鼻息肉、哮喘和对环氧化酶-1抑制类药物的不耐受。AERD的发病机制尚不完全清楚,公认的观点是该病由花生四烯酸代谢异常引起。由于对该疾病的认识不足,很多临床医师对此病无法做出准确的诊断,严重影响患者后续的治疗效果。对症药物处理、手术、阿司匹林脱敏和生物制剂是目前临床治疗AERD的主要手段。笔者主要就AERD的发病机制和治疗策略进行综述。

关键词: 阿司匹林, 阿司匹林加重呼吸系统疾病, 治疗应用, 方案评价

Abstract:

Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by chronic rhinosinusitis with nasal polyps, asthma, and hypersensitivity to cyclooxygenase-1 (COX-1) inhibitors. Although the precise pathogenesis of AERD remains unclear, it is widely acknowledged that aberrant metabolism of arachidonic acid plays a central role in the development of this condition. Owing to the incomplete understanding of AERD, many clinicians struggle to establish an accurate diagnosis, which significantly compromises treatment outcomes. Current therapeutic approaches primarily include symptomatic pharmacological management, surgical interventions, aspirin desensitization, and the use of biologic agents. The author aims to provide a comprehensive overview of the pathogenesis and therapeutic strategies for AERD.

Key words: Aspirin, Aspirin-exacerbated respiratory diseases, Therapeutic uses, Program evaluation

中图分类号:

明文华, 马婷婷, 王洪田, 王学艳. 阿司匹林加重呼吸系统疾病:发病机制和治疗策略[J]. 中国防痨杂志, 2024, 46(11): 1400-1405. doi: 10.19982/j.issn.1000-6621.20240216

Ming Wenhua, Ma Tingting, Wang Hongtian, Wang Xueyan. Aspirin-exacerbated respiratory diseases: pathogenesis and treatment strategies[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1400-1405. doi: 10.19982/j.issn.1000-6621.20240216

参考文献 44

[1]	Rajan JP, Wineinger NE, Stevenson DD, et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol, 2015, 135(3): 676-681. e1. doi:10.1016/j.jaci.2014.08.020. pmid: 25282015
[2]	Dominas C, Gadkaree S, Maxfield AZ, et al. Aspirin-exacerbated respiratory disease: A review. Laryngoscope Investig Otolaryngol, 2020, 5(3): 360-367. doi:10.1002/lio2.387. pmid: 32596477
[3]	Hahn J, Appel H, Scheithauer MO, et al. Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid. Am J Rhinol Allergy, 2020, 34(4): 554-563. doi:10.1177/1945892420912362. pmid: 32208749
[4]	Laidlaw TM, Levy JM. NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets. Curr Allergy Asthma Rep, 2020, 20(4): 10. doi:10.1007/s11882-020-00905-9.
[5]	Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol, 2021, 11(3): 213-739. doi:10.1002/alr.22741.
[6]	Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis, 1991, 144(4): 957-958. doi:10.1164/ajrccm/144.4.957.
[7]	San Nicoló M, Habermann N, Havel M. AERD Associated Nasal Polyposis: Efficacy of Postoperative Antileukotriene Therapy in Comparison with Aspirin Desensitization. A Retrospective Study. Int Arch Allergy Immunol, 2020, 181(10): 790-798. doi:10.1159/000508708.
[8]	Li KL, Lee AY, Abuzeid WM. Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and Management. Med Sci (Basel), 2019, 7(3): 45. doi:10.3390/medsci7030045.
[9]	Laidlaw TM, Gakpo DH, Bensko JC, et al. Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract, 2020, 8(9): 3170-3171. doi:10.1016/j.jaip.2020.06.061. pmid: 32739465
[10]	Makary CA, Holmes T, Unsal A, et al. Long-term role of zileuton in the treatment of chronic rhinosinusitis in aspirin exacerbated respiratory disease. Am J Otolaryngol, 2022, 43(1): 103227. doi:10.1016/j.amjoto.2021.103227.
[11]	Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax, 1994, 49(8): 749-756. doi:10.1136/thx.49.8.749. pmid: 8091318
[12]	Sansing-Foster V, Haug N, Mosholder A, et al. Risk of Psychiatric Adverse Events Among Montelukast Users. J Allergy Clin Immunol Pract, 2021, 9(1): 385-393. e12. doi:10.1016/j.jaip.2020.07.052. pmid: 32795564
[13]	Cetkovská P, Pizinger K. Childhood pemphigus associated with montelukast administration. Clin Exp Dermatol, 2003, 28(3): 328-329. doi:10.1046/j.1365-2230.2003.01266.x.
[14]	Di Salvo E, Patella V, Casciaro M, et al. The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients. Pulm Pharmacol Ther, 2020, 60: 101875. doi:10.1016/j.pupt.2019.101875.
[15]	Incecik F, Onlen Y, Sangun O, et al. Probable montelukast-induced hepatotoxicity in a pediatric patient: case report. Ann Saudi Med, 2007, 27(6): 462-463. doi:10.5144/0256-4947.2007.462. pmid: 18059126
[16]	Wooltorton E. Asthma drug zafirlukast (Accolate): serious hepatic events. CMAJ, 2004, 170(11): 1668. doi:10.1503/cmaj.1040720.
[17]	Watkins PB, Dube LM, Walton-Bowen K, et al. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf, 2007, 30(9): 805-815. doi:10.2165/00002018-200730090-00006.
[18]	Mendelsohn D, Jeremic G, Wright ED, et al. Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann Otol Rhinol Laryngol, 2011, 120(3): 162-166. doi:10.1177/000348941112000304.
[19]	Sweis AM, Locke TB, Ig-Izevbekhai KI, et al. Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease. Allergy Asthma Proc, 2021, 42(2): 136-141. doi:10.2500/aap.2021.42.210002. pmid: 33685558
[20]	Bosso JV. Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: Clinical perspective. Int Forum Allergy Rhinol, 2021, 11(4): 822-823. doi:10.1002/alr.22709.
[21]	Walters KM, Waldram JD, Woessner KM, et al. Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease. Am J Rhinol Allergy, 2018, 32(4): 280-286. doi:10.1177/1945892418770260. pmid: 29682983
[22]	Stevens WW, Jerschow E, Baptist AP, et al. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol, 2021, 147(3): 827-844. doi:10.1016/j.jaci.2020.10.043.
[23]	Taniguchi M, Mitsui C, Hayashi H, et al. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD. Allergol Int, 2019, 68(3): 289-295. doi:10.1016/j.alit.2019.05.001. pmid: 31235242
[24]	Locke TB, Sweis AM, Gleeson PK, et al. Age as a factor in treatment of aspirin-exacerbated respiratory disease: relationship to required aspirin maintenance dose after desensitization. Int Forum Allergy Rhinol, 2020, 10(10): 1180-1181. doi:10.1002/alr.22665.
[25]	D’Souza GE, Nwagu U, Barton B, et al. Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics. Int Forum Allergy Rhinol, 2022, 12(3): 306-309. doi:10.1002/alr.22900.
[26]	Bavaro N, Gakpo D, Mittal A, et al. Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting. J Allergy Clin Immunol Pract, 2021, 9(7): 2910-2912. e1. doi:10.1016/j.jaip.2021.02.020. pmid: 33631410
[27]	Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med, 2018, 378(26): 2486-2496. doi:10.1056/NEJMoa1804092.
[28]	Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol, 2022, 149(4): 1286-1295. doi:10.1016/j.jaci.2021.09.009.
[29]	Mustafa SS, Vadamalai K, Scott B, et al. Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease. Am J Rhinol Allergy, 2021, 35(3): 399-407. doi:10.1177/1945892420961969.
[30]	Patel P, Bensko JC, Bhattacharyya N, et al. Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol, 2022, 128(3): 326-328. doi:10.1016/j.anai.2021.11.020.
[31]	Buchheit KM, Laidlaw TM, Levy JM. Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 2021, 148(2): 348-350. doi:10.1016/j.jaci.2021.06.019. pmid: 34174296
[32]	Tuttle KL, Buchheit KM, Laidlaw TM, et al. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract, 2018, 6(3): 1045-1047. doi:10.1016/j.jaip.2018.01.038. pmid: 29501519
[33]	Wangberg H, Spierling Bagsic SR, Osuna L, et al. Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract, 2022, 10(2): 478-484. e3. doi:10.1016/j.jaip.2021.09.030.
[34]	Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2021, 9(10): 1141-1153. doi:10.1016/S2213-2600(21)00097-7. pmid: 33872587
[35]	Buchheit KM, Lewis E, Gakpo D, et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 2021, 148(2): 574-584. doi:10.1016/j.jaci.2021.05.043. pmid: 34144111
[36]	Workman AD, Bleier BS. Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost. World J Otorhinolaryngol Head Neck Surg, 2020, 6(4): 230-234. doi:10.1016/j.wjorl.2020.06.002.
[37]	Hayashi H, Mitsui C, Nakatani E, et al. Omalizumab reduces cysteinyl leukotriene and 9alpha,11beta-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 2016, 137(5): 1585-1587. e4. doi:10.1016/j.jaci.2015.09.034.
[38]	Hayashi H, Fukutomi Y, Mitsui C, et al. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial. Am J Respir Crit Care Med, 2020, 201(12): 1488-1498. doi:10.1164/rccm.201906-1215OC.
[39]	Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol, 2020, 146(3): 595-605. doi:10.1016/j.jaci.2020.05.032. pmid: 32524991
[40]	Quint T, Dahm V, Ramazanova D, et al. Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization. J Allergy Clin Immunol Pract, 2022, 10(2): 506-516. e6. doi:10.1016/j.jaip.2021.09.050.
[41]	Schneider TR, Johns CB, Palumbo ML, et al. Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial. J Allergy Clin Immunol Pract, 2018, 6(3): 825-831. doi:10.1016/j.jaip.2017.10.011. pmid: 29133219
[42]	Laidlaw TM, Cahill KN, Cardet JC, et al. A trial of type 12 purinergic (P2Y(12)) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 2019, 143(1): 316-324. e7. doi:10.1016/j.jaci.2018.06.001. pmid: 29890239
[43]	Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med, 2017, 377(10): 936-946. doi:10.1056/NEJMoa1704064.
[44]	Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med, 2021, 384(19): 1800-1809. doi:10.1056/NEJMoa2034975.

阿司匹林加重呼吸系统疾病:发病机制和治疗策略

Aspirin-exacerbated respiratory diseases: pathogenesis and treatment strategies

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	朱建坤, 孟倩, 孔康宝, 金锋. 全肺切除术在肺毛霉菌病治疗中的价值[J]. 中国防痨杂志, 2025, 47(3): 274-281.
[2]	何忠良, 徐卫华, 辛顺心, 陈国兴, 何雪明, 王磊. 个体化精准治疗在闭合肺癌切除术后支气管胸膜瘘中的应用价值[J]. 中国防痨杂志, 2025, 47(3): 282-286.
[3]	吴倩, 王伟, 张钰, 陈松华, 陈彬. 浙江省无结核社区评价指标体系构建[J]. 中国防痨杂志, 2025, 47(3): 331-337.
[4]	中国防痨协会《中国防痨杂志》编辑委员会首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所 Inspire⁃CODA研究组. 康替唑胺治疗结核病专家共识[J]. 中国防痨杂志, 2025, 47(2): 123-129.
[5]	李雪莲, 张红燕, 王隽, 王庆枫, 马丽萍, 初乃惠, 聂文娟. 耐药肺结核患者超疗程使用德拉马尼的安全性分析[J]. 中国防痨杂志, 2025, 47(2): 164-168.
[6]	肖聪, 蒋余强, 钟丹. 急性期糖皮质激素联合阿司匹林和丙种球蛋白治疗高危评分患儿川崎病合并肺炎支原体感染的疗效分析[J]. 中国防痨杂志, 2024, 46(S2): 172-174.
[7]	胡煜晨. 慢性阻塞性肺疾病的中西医康复疗法[J]. 中国防痨杂志, 2024, 46(S2): 542-544.
[8]	李杨, 孙峰, 张文宏. 结核病短程治疗研究:回顾与展望[J]. 中国防痨杂志, 2024, 46(9): 991-997.
[9]	段鸿飞. 非结核分枝杆菌病诊治六十年[J]. 中国防痨杂志, 2024, 46(8): 863-868.
[10]	王煜童, 刘宇红. 世界卫生组织《关于耐药结核病治疗关键性修订的快速通告》解读[J]. 中国防痨杂志, 2024, 46(11): 1303-1305.
[11]	沙巍. PAN-TB治疗策略的实施对结核病防控的意义及挑战[J]. 中国防痨杂志, 2024, 46(10): 1188-1192.
[12]	闫红璇, 袁金锋, 王艺霖, 逄宇, 高孟秋. 结核病宿主导向治疗的研究进展[J]. 中国防痨杂志, 2024, 46(10): 1273-1282.
[13]	付亮, 邓国防. MDR-Chin研究解析:耐多药肺结核全口服短程治疗方案在中国的应用前景[J]. 中国防痨杂志, 2024, 46(1): 18-22.
[14]	程耀, 陈洪德, 吴桂辉, 赖敏, 罗海霞, 崔坤平, 李玉科. 结核性毁损肺行有创机械通气治疗患者死亡相关因素分析[J]. 中国防痨杂志, 2023, 45(7): 651-657.
[15]	中国人民解放军总医院第八医学中心结核病医学部, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会. 浅表淋巴结结核的诊断与治疗专家共识[J]. 中国防痨杂志, 2023, 45(6): 531-542.